Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-18

Clinical Trial Update: An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating efficacy and safety of tocilizumab (RoActemra/Actemra) in Giant Cell Arteritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Giant Cell Arteritis | Phase 3 | Status: COMPLETED | Results posted: 2017-05-18